myirislogo
31 August, 2015 20:48 IST
My Last 5 Scrips
Company BSE Price (Rs) % Chg
Tata Power 60.70 0.57
State Bank O 247.10 0.86
Sslt 98.60 2.34
Tata Stl 225.05 1.51
Tata Motors 340.15 0.07
Clear All Clear Last
   
NSE Live
Nifty Live Prices
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
Advances / Declines new
Index Weightage new
Exchange Holidays new
Nse Sectors new
Contribution To Index new
Bonus new
Rights new
Delisted-Shares new
Split of Value new
BSE Live
BSE30 Live Prices
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
Advances / Declines new
Index Weightage new
Exchange Holidays new
Bse Sectors new
Contribution To Index new
Bonus new
Rights new
Delisted-Shares new
Split of Value new
Market Pulse
Leaders
Laggards
FII Activity
Mutual Fund Activity
Meetings
Results Watch
Results Calendar
Results Announced
Watch
Sector Watch
Economy Watch
Company
Snapshots
Quotes
Charts
Financials
Recent News
Broker Research
Meetings
Research Tutorial
Research
Research Reports
Snapshot-Piramal Enterprises Limited
Piramal Enterprises Limited
Sector:Pharmaceuticals Pharmaceuticals - Formulations
BSE:500302NSE:PELBloomberg:PIEL@INReuters:PIRA.BO
Market Lot: 1Face Value: 2ISIN Demat: INE140A01024
QuotesSnapshotChartsFinancialsResearchRecent News
Peer GroupAGM/AMMF HoldingDiscussion ForumBSE/NSE NoticesBSE/NSE Deals

 
 
Recent Developments
17-APR-15 Piramal Enterprises today announced that it has agreed to acquire a majority stake in Health SuperHiway, a healthcare analytics company, over the next 12 months. 01-APR-15 Piramal Enterprises announced Wednesday it has signed a definitive agreement to sell its clinical research division known as Piramal Clinical Research (PCR), formerly known as Wellquest, to Indoco Remedies (Indoco) on a going concern basis for cash. 09-FEB-15 Dur...   More..
Business Profile Future Plans
CEO Talk
Nicholas Piramal is confident that it will survive in the post-2005 era, when product patents become effective as it aims to partner multinational companies.   Vijay Shah
One To One
Recent news
Latest News
Piramal sells clinical research division to Indoco  -IRIS 01-Apr-15
Previous

More


Brief Financials (in Rs. Mn.)Detailed Quarterly
Period ending (months)30-Jun-2015(3)31-Mar-2015 (12)31-Mar-2014 (12)
Net sales 6944.5022797.3018134.70
Other Income1269.602985.901868.60
Total Income8214.1025783.2020003.30
Cost of goods sold5082.1019567.5017791.40
OPBDIT3132.006215.702211.90
PAT1731.403727.40-3700.00
Gross Block---
Equity capital345.10345.10345.10
EPS (Rs.)-21.60-21.40
DPS (Rs.)---
BV (Rs.)---
P/E range (x)-24.17 - 43.93NA
Debt / Equity (x)---
Operating margin (% of OI)38.124.111.1
Net margin (% of OI)21.114.5-18.5
Detailed Financials
Income 
Statement
Balance Sheet Latest 
Quarterly/Halfyearly
Ratio Analysis Share Statistics
Price Charts
Scrip Information



Registered Office
ADDRESS
Piramal Tower Annexe
Ganpatrao Kadam Marg
Lower Parel
Mumbai
Maharashtra-400 013
PHONE
(022) 3046 7953
FAX
(022) 2490 2363
 
Board of Directors
NSE/BSE Announcements


Home | Shares | F&O | Mutual Funds | Loans | Insurance | News Centre
Wealth Tracker | Tax Corner | NRI Centre | Search in myiris | Advertise
All rights reserved. IRIS Business Services Limited
Disclaimer